Masakazu Matsumoto

Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-Ay/Ta mice

Mitsuo Tanimoto, Tomohito Gohda, Shigeru Kaneko et al. · Metabolism · 2007 · 91 citations

Medicine, Endocrinology, Pharmacology +13

Glomerular changes in the KK‐A^y/Ta mouse: A possible model for human type 2 diabetic nephropathy

Takamichi Ito, Mitsuo Tanimoto, Kaori Yamada et al. · Nephrology · 2006 · 62 citations · Full text

Medicine, Endocrinology, Pathology +17

Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function

Tomohito Gohda, Mitsuo Tanimoto, Ju-Young Moon et al. · Diabetes Research and Clinical Practice · 2008 · 50 citations

Medicine, Endocrinology, Nephrology +15

Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice

Shinji Hagiwara, Tomohito Gohda, Mitsuo Tanimoto et al. · Metabolism · 2009 · 41 citations

Medicine, Endocrinology, Pharmacology +12

Purification of a Protective Antigen from a Saline Extract of <i>Pasteurella multocida</i>

Bunei Syuto, Masakazu Matsumoto · Infection and Immunity · 1982 · 34 citations · Full text

Life Sciences, Biochemistry, Immunology +13